期刊文献+

筛选介导化学合成siRNA转染原代肝癌细胞的最佳试剂 被引量:3

Transfection agents screening for chemosynthesis siRNA transfection to primary liver cancer cells
下载PDF
导出
摘要 背景:理想的细胞转染试剂应具有高效安全的特点。目的:筛选能够高效介导化学合成siRNA转染原代肝癌细胞的最佳转染试剂。方法:应用Lipofectamine RNAiMAX,Lipofectamine2000和DharmaFECT1转染试剂介导FAM-siRNA和多药耐药基因MDR1siRNA转染原代肝癌细胞,分别于转染6和48h后应用流式细胞仪和实时荧光定量PCR检测转染效率,然后用MTT法检测3种转染试剂处理原代肝癌细胞24h后的细胞毒性。结果与结论:对于Lipofectamine RNAiMAX,Lipofectamine2000和DharmaFECT1转染试剂介导的FAM-siRNA和MDR1siRNA转染,流式细胞仪和实时荧光定量PCR仪检测出RNAiMAX转染效率最高(P<0.05),分别为70.3%和71.5%。MTT法检测结果表明RNAiMAX对原代肝癌细胞没有表现出细胞毒性。结果提示,由于RNAiMAX介导的FAM-siRNA和MDR1siRNA转染的效率最高,并且对细胞的毒性最小,所以RNAiMAX是最适合介导化学合成siRNA转染原代肝癌细胞的转染试剂。 BACKGROUND:The ideal transfection agent should efficient and low-toxic.OBJECTIVE:To screen transfection agent which efficiently transfect chemosynthesis siRNA to primary liver cancer cells.METHODS:FAM-siRNA and MDR1 siRNA was transfected to primary liver cancer cells by Lipofectamine RNAiMAX,Lipofectamine 2000 and DharmaFECT1.The transfection efficiency was evaluated by flow cytometer and real time-PCR at 6 and 48 hours after transfection.Moreover,the cytotoxicity of transfection agents in primary liver cancer cells was tested by MTT method.RESULTS AND CONCLUSIONS:The results of flow cytometer and real time-PCR indicated that,the transfection efficiency of siRNA tranfection to primary liver cancer cells mediated by RNAiMAX was highest (P0.05),which was 70.3% and 71.5%,respectively.The cytotoxicity of RNAiMAX in primary liver cancer cells did not show in MTT detection (P0.05).RNAiMAX was suitable to transfect siRNA to primary liver cancer cells because the efficiency of siRNA tranfection to primary liver cancer cells mediated by RNAiMAX was the highest and the cytotoxicity of RNAiMAX in primary liver cancer cells was the lowest.
出处 《中国组织工程研究与临床康复》 CAS CSCD 北大核心 2011年第2期245-248,共4页 Journal of Clinical Rehabilitative Tissue Engineering Research
基金 临沂师范学院立项课题(HX10602)资助课题名称:抗肝癌药物及其分子机制研究~~
  • 相关文献

参考文献1

二级参考文献14

  • 1Hartenbach EM,,Olson TA,Goswitz JJ,Mohanraj D,Twiggs LB,Carson LF,Ramakrishnan S.Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Letters . 1997
  • 2Kumar H,Heer K,Lee PW,Duthie GS,MacDonald AW,Greenman J,Kerin MJ,Monson JR.Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clinical Cancer Research . 1998
  • 3Volm M,Koomagi R,Mattern J,et al.Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. International Journal of Cancer . 1997
  • 4Ferrara N,Gerber HP,LeCouter J.The biology of VEGF and its receptors. Nature Medicine . 2003
  • 5Zachary I,Gliki G.Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovascular Research . 2001
  • 6Harborth J,Elbashir SM,Bechert K,et al.Identification of essential genes in cultured mammalian cells using small interfering RNAs. Journal of Cell Science . 2001
  • 7Hannon GJ.RNA interference. Nature . 2002
  • 8Wannenes F,Ciafre SA,Niola F,et al.Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo. Cancer Gene Therapy . 2005
  • 9KR Molhoek,H Griesemann,J Shu,JE Gershenwald,DL Brautigan,CL Slingluff.Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Research . 2008
  • 10S Wang,H Liu,L Ren,Y Pan,Y Zhang.Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference. Neoplasia . 2008

共引文献8

同被引文献35

  • 1石智,符立梧.RNAi及其在肿瘤研究中的应用[J].生物化学与生物物理进展,2004,31(6):492-499. 被引量:11
  • 2林兆宇,高翔.小鼠的遗传学研究[J].生命科学,2006,18(5):437-441. 被引量:10
  • 3朱利斌,刘征吉,李仲荣,李东,陈肖鸣.大鼠肠神经干细胞分离和体外培养的初步研究[J].温州医学院学报,2007,37(1):5-8. 被引量:8
  • 4Fire A, Xu S, Montgomery MK, et al. Potent and specific geneticinterference by double-stranded RNA in Caenorhabditis elegans.Nature, 1998, 391(6669):806-811.
  • 5Hammond SM, Bernstein E, Beach D, et al. An RNA-directednuclease mediates post-transcriptional gene silencing in Drosophilacells. Nature, 2000,404(6775):293-296.
  • 6Tuschl T, Borkhardt A. Small interfering RNAs: a revolutionary toolfor the analysis of gene function and gene therapy. Mol Interv, 2002,2(3):158-167.
  • 7Caplen NJ, Parrish S, Imani F, et al. Specific inhibition of geneexpression by small double-stranded RNAs in invertebrate andvertebrate systems. Proc Natl Acad Sci USA, 2001, 98(17):9742-9747.
  • 8Elbashir SM, Harborth J,Weber K, et al. Analysis of gene function insomatic mammalian cells using small interfering RNAs. Methods,2002,26(2):199-213.
  • 9McManus MT. Small RNAs and immunity. Immunity, 2004, 21(6):747-756.
  • 10de Fougerolles A, Vomlocher HP, Maraganore J, et al. Interfering withdisease: a progress report on siRNA-based therapeutics. Nat Rev DrugDiscov, 2007, 6(6):443-453.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部